Alpha-synuclein aggregation inhibitor - AC Immune
Alternative Names: ACI-5755; Morphomer a-syn - AC Immune; Morphomer alpha-synuclein - AC ImmuneLatest Information Update: 27 Feb 2024
At a glance
- Originator AC Immune
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 27 Feb 2024 Alpha-synuclein aggregation inhibitor is still in preclinical trials for Parkinson's disease in Switzerland
- 28 Mar 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in Switzerland
- 04 May 2020 AC Immune plans to identify first biologically active small molecule in Q2 2020